回肠造口还纳术前直肠刺激联合益生菌与益生元:随机对照试验研究方案
本方案为开放标签随机对照临床试验,纳入接受新辅助放化疗及腹腔镜或机器人全直肠系膜切除术的cT3/4Nx或cTxN+期直肠癌成人患者,比较回肠造口还纳术前15天每日直肠给予含6 g Simbioflora®的500 ml生理盐水与直接还纳的疗效,主要结局为术后无动力性肠梗阻及肠道传输时间。
要点
- 干预组在造口还纳前15天每日直肠给予500 ml生理盐水加6 g Simbioflora®。
- 主要结局为无动力性肠梗阻和肠道传输,后者以首次排气或排便时间评估。
- 无动力性肠梗阻定义为术后72小时内需置胃管、恶心呕吐或无法耐受经口进食。
核心结论
- 本随机对照试验的研究发现可能对回肠造口还纳患者的管理产生重要影响。
研究设计与样本
- 开放标签随机对照临床试验的研究方案,已获伦理批准(CAAE: 56551722.6.0000.0071)。
- 纳入标准为:接受袢式保护性回肠造口的cT3/4Nx或cTxN+期直肠癌成人患者;接受新辅助放化疗者;接受腹腔镜或机器人全直肠系膜切除术者。
主要发现
- 干预组(直肠刺激组)在回肠造口还纳前15天每日一次直肠给予500 ml生理盐水加6 g Simbioflora®;对照组(无直肠刺激组)直接还纳造口,术前无直肠刺激。
- 主要结局为无动力性肠梗阻(术后72小时内需置胃管、恶心呕吐或无法耐受经口进食)和肠道传输(首次排气或排便时间)。
- 患者入组于2023年1月开始,预计2025年7月完成。
- 研究已在巴西临床试验注册中心(ReBEC)注册,注册号RBR-366n64w,注册日期为2022年7月19日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ileostomy closure is associated with a high rate of postoperative morbidity, and adynamic ileus is the most common complication, with an incidence of up to 32%. This complication is associated with delayed initiation of oral diet intake, abdominal distention, prolonged hospital stay, and more significant patient discomfort. The present study aims to evaluate the rectal stimulus with prebiotics and probiotics before ileostomy reversal. METHODS: This is a protocol study for an open-label randomized controlled clinical trial. Ethical approval was received (CAAE: 56551722.6.0000.0071). The following criteria will be used for inclusion: adult patients with rectal cancer stages cT3/4Nx or cTxN+ that underwent loop protection ileostomy, patients treated with neoadjuvant chemoradiotherapy, and patients who underwent laparoscopic or robotic total mesorectal excision. Patients will be randomized to one of two groups. The intervention group (with rectal stimulus): the patients will apply 500 ml of saline solution with 6 g of Simbioflora® rectally, once a day, for 15 days before ileostomy closure. The control group (without rectal stimulation): the patients will close the ileostomy with no previous rectal stimulus. The primary outcomes will be the adynamic ileus (need for postoperative nasogastric tube insertion; nausea/vomiting; or intolerance to oral feedings within the first 72 h) and intestinal transit (time to first evacuation/flatus). RESULTS: The patient's enrollment starts in January 2023. We expect to finish in July 2025. DISCUSSION: The findings of this randomized clinical study may have important implications for managing patients undergoing ileostomy reversal. TRIAL REGISTRATION: This study is registered in the Brazilian Trial Registry (ReBEC) under RBR-366n64w. Registration date: 19/07/2022.
引用
- Marcelino M, Tustumi F, Gerbasi LS, et al. Rectal stimulation with prebiotics and probiotics before ileostomy reversal: a study protocol for a randomized controlled trial. Trials. 2023. PMID: 36647079. doi:10.1186/s13063-023-07065-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。